Neurochemical Pathways That Converge on Thalamic Trigeminovascular Neurons: Potential Substrate for Modulation of Migraine by Sleep, Food Intake, Stress and Anxiety

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation
Noseda, Rodrigo, Vanessa Kainz, David Borsook, and Rami Burstein. 2014. “Neurochemical Pathways That Converge on Thalamic Trigeminovascular Neurons: Potential Substrate for Modulation of Migraine by Sleep, Food Intake, Stress and Anxiety.” PLoS ONE 9 (8): e103929. doi:10.1371/journal.pone.0103929. http://dx.doi.org/10.1371/journal.pone.0103929.

Published Version
doi:10.1371/journal.pone.0103929

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:12785968

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Neurochemical Pathways That Converge on Thalamic Trigeminovascular Neurons: Potential Substrate for Modulation of Migraine by Sleep, Food Intake, Stress and Anxiety

Rodrigo Noseda¹, Vanessa Kainz¹, David Borsook², Rami Burstein¹

¹ Department of Anesthesiology, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America, ² Department of Anesthesiology, Perioperative and Pain Medicine, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America

Abstract

Dynamic thalamic regulation of sensory signals allows the cortex to adjust better to rapidly changing behavioral, physiological and environmental demands. To fulfill this role, thalamic neurons must themselves be subjected to constantly changing modulatory inputs that originate in multiple neurochemical pathways involved in autonomic, affective and cognitive functions. Our overall goal is to define an anatomical framework for conceptualizing how a ‘decision’ is made on whether a trigeminovascular thalamic neuron fires, for how long, and at what frequency. To begin answering this question, we determine which neuropeptides/neurotransmitters are in a position to modulate thalamic trigeminovascular neurons. Using a combination of in-vivo single-unit recording, juxtacellular labeling with tetramethylrhodamine dextran (TMR) and in-vitro immunohistochemistry, we found that thalamic trigeminovascular neurons were surrounded by high density of axons containing biomarkers of glutamate, GABA, dopamine and serotonin; moderate density of axons containing noradrenaline and histamine; low density of axons containing orexin and melanin concentrating hormone (MCH); but not axons containing CGRP, serotonin 1D receptor, oxytocin or vasopressin. In the context of migraine, the findings suggest that the transmission of headache-related nociceptive signals from the thalamus to the cortex may be modulated by opposing forces (i.e., facilitatory, inhibitory) that are governed by continuous adjustments needed to keep physiological, behavioral, cognitive and emotional homeostasis.

Introduction

Historically, the thalamus was viewed as a simple relay station for sensory information from the periphery to the cortex. This view has been replaced by the concept that instead of ‘just’ transferring sensory signals from subcortical nuclei to the cortex, thalamic neurons play central role in the selection, amplification, and prioritization process that determines which type of information should be made available to the cortex at any given time [1,2]. Being the so-called ‘gate-keeper’ of the cortex, thalamic neurons regulate the flow of rapidly-changing sensory signals, thus allowing the cortex to adjust to the constantly evolving behavioral and environmental demands [1].

To regulate the amount of sensory signals that reach the cortex, thalamic neurons must themselves be subjected to a variety of modulatory inputs that originate in cortical, hypothalamic, brainstem, spinal and intrathalamic nuclei [1,3–6]. In the context of somatosensory and nociceptive information, the more extensively studied networks that drive and/or modulate the activity of relay thalamic neurons are the excitatory glutamatergic input originating in corticothalamic, spinothalamic and medial lemniscus tract neurons, and the inhibitory GABAergic input involving the reticular thalamic nucleus [7,8]. The excitatory glutamate input, acting through metabotropic mGluRs, is capable of producing sustained neuronal firing whereas the inhibitory GABA input, acting through the GABAβ receptor is capable of switching off the sustained neuronal activity [8].

Far less is known about the regulation of relay thalamic neurons by other neurotransmitters and neuropeptides [3] from various brain regions. Candidates include those from the brainstem and hypothalamus. Brainstem inputs include serotonergic projections from raphe nuclei [9,10], noradrenergic projections from locus coeruleus and the A5 catecholamine group in thepons [9–11], and dopaminergic projections from periaqueductal gray, and the lateral parabrachial nucleus [12–16]. Hypothalamic inputs include additional dopaminergic projections from A11/A13 [12–16], histaminergic projections from the tuberomammillary nucleus [17,18], orexinergic projections from the perifornical, dorsomedial and lateral hypothalamus [19,20], and melanin-concentrating hormone (MCH) projections from the lateral hypothalamus [21–23].
The potential release of these neurotransmitters/neuropeptides on relay thalamic nuclei suggests that the modulation of individual neurons is rather complex, likely subjected to opposing forces driven by a variety of changing external and internal conditions that require constant behavioral, physiological, and affective adjustments. Our overall goal is to understand how a decision is made on whether or not a relay thalamic neuron fires, for how long, and at what frequency. To start answering this question, we must first determine which neurotransmitters/neuropeptides are in a position to govern the activity of individual thalamic neurons that share a common function; a task never taken before. In the current study we describe an array of neurotransmitters/neurotransmitters that may modulate individual, physiologically-identified thalamic trigeminovascular neurons believed to play a role in the generation of headache perception during migraine. The understanding of this neurobiology will allow for a basis to determine functional neurotransmission between the thalamus and cortex related to multiple clinical components of migraine including pain (somatosensory cortex), cognition (frontal cortex), memory (hippocampus), altered perception (parietal cortex), interoception and awareness (insula cortex).

**Materials and Methods**

**Animal preparation**
Experiments were approved by the Institutional Animal Care and Use Committee at Harvard Medical School and Beth Israel Deaconess Medical Center, and conducted in accordance of NIH guide for the care and use of laboratory animals. Thirty-two male Sprague-Dawley rats weighing 250–350 g were initially anesthetized with a single dose of Breval sodium (45 mg/kg i.p.) to allow endotracheal intubation and cannulation of the right femoral vein. Each rat was then mounted on a stereotaxic frame and connected to an inhalation anesthesia system (O2/Isoflurane 2.5% for craniotomies; 1–1.2% for maintenance during the rest of the experiment). The rats were then frozen and cut into serial coronal sections (60–80 μm).

**Single-unit juxtacellular recording and iontophoresis**
A glass micropipette (20–50 MΩ impedance) filled with a 3% solution of the tracer tetramethylrhodamine dextran (TMR; 3,000 MW, anionic, lysine fixable; D-3308, Invitrogen) in 0.9% NaCl, was lowered into the right posterior thalamus while searching for single-unit responses to electrical stimulation of the contralateral dura (0.8 ms, 0.5–3.0 mA, 1 Hz). Thalamic neurons responding to the electrical stimulation were additionally tested for responses induced by mechanical (calibrated von-Frey monofilament) and chemical (1 M KCl solution) stimulation of the dura (Fig. 1A). Response was defined as an increase in firing rate that was at least 50% higher than baseline. Spikes from neurons responding to all three types of stimuli were amplified, filtered and acquired in a window discriminator to be further analyzed using Spike2 software (CED, Cambridge, UK). Once the electrophysiological characterization of neuronal responses was finalized, the cell was iontophoretically injected using the recording glass micropipette by delivering pulses of positive current (1–10 nA) at 250-ms on/off intervals by means of a computer-controlled microelectrode amplifier (Axoclamp 900A, Molecular Devices), as described elsewhere [23] (Fig. 1B).

**Histological processing**
Rats were injected with an overdose of pentobarbital sodium (100 mg/kg) and perfused intracardially with 200 ml heparinized saline, followed by a fixative solution consisting in 400 ml of 0.1 M phosphate buffered saline (PBS), 4% paraformaldehyde and 0.05% picric acid. Only when required for the staining protocol, rats were perfused with 200 ml of PBS followed by a fixative solution containing 75 ml of 4% ethylenediamine in 0.1 M PBS. Brains were removed, soaked in the fixative solution for 2 hrs, and cryoprotected in 30% sucrose phosphate buffer for 48 hrs. Brains were then frozen and cut into serial coronal sections (60–80 μm).

**Figure 1. Identification and labeling of individual thalamic trigeminovascular neurons.** (A) Neuronal responses to electrical (1 mA, 0.8 ms), mechanical (von Frey filament: 4, 63 g) and chemical (1 M KCl solution) stimulation of the dura overlying the left transverse sinus. (B) Synchronization of neuronal activity during iontophoretic injection of TMR by delivering pulses of current (1–10 nA) at 250 ms on/off intervals through the recording glass micropipette. doi:10.1371/journal.pone.0103929.g001

---

**Disclosure**

The authors have declared no conflict of interest.
thick) using a cryostat (Leica). Free-floating sections were collected and mounted on slides for a rapid visualization and localization of each cell body and its dendrites using epifluorescence microscopy.

Immunofluorescence

Brain sections containing successfully injected neurons were pre-incubated at room temperature in PBS containing 2% fetal bovine serum albumin (FSA) and 1% Triton X-100 for 1 hr. Sections were then incubated at 4°C for 48 hrs in the same blocking solution with one of the following primary antibodies: (i) mouse anti-Serotonin Transporter, SERT (1:5,000 dilution; Millipore); (ii) mouse anti-Tyrosine Hydroxylase, TH (1:5,000; Immunostar); (iii) rabbit anti-Dopamine β-Hydroxylase, DBH (1:5,000; Immunostar); (iv) goat anti-Orexin A (1:2,500; Santa Cruz); (v) rabbit anti-Calcitonin Gene Related Peptide, CGRP (1:5,000; Chemicon); (vi) rabbit anti-5HT1D receptor (1:50,000; Courtesy of Andrew Ahn, University of Florida); (vii) rabbit anti-Oxytocin (1:10,000; Immunostar); (viii) goat anti-Vasopressin (1:1,000; Immunostar); (ix) rabbit anti-Histamine (1:3,000; Immunostar; ethylcarbodiimide perfusion); (x) guinea pig anti-Vesicular Glutamate Transporter 2, VGluT2 (1:1,000; Phosphosolutions); (xi) Melanin Concentrating Hormone, MCH (1:1,000; Courtesy of Terry Maratos-Flier, Harvard Medical School). The sections were washed multiple times and then incubated in PBS containing 2% FSA and 0.5% Triton X-100 for 2 hrs at room temperature with the corresponding fluorescent secondary antibody (Alexa Fluor 488; Invitrogen) against the Ig’s of the animal in which the primary antibody was raised (dilution range 1:200–1:1,000). Immunostained sections were serially mounted on glass slides and overslipped with fluorescent mounting media with or without DAPI counterstaining.

Digital imaging of thalamic labeling

Digital imaging of each of the neuronal cell bodies and dendrites injected with TMR, as well as the axonal network of the different neurotransmitters/neuropeptides was performed using epifluorescence scanning microscopy that compiled 1–1.5 μm-thick scans using z-stacking software (Leica). Using individual z-stack images, orthogonal views of the y-z and x-z planes were also created to provide additional evidence for close apposition, and thus probable contact. Immunofluorescent labeling of TMR was determined using vesicular GABA transporter (VGaT) (1:1,500; Immunostar), a stable marker of inhibitory neurotransmission. VGaT immunoreactive axons and varicosities were seen in close apposition to the cell body, proximal and distal dendrites (Fig. S3). These DBH axons originate in the locus coeruleus, the main producer of noradrenaline in the brain.

Results

Identification and juxtacellular labeling of thalamic trigeminovascular neurons

Forty-seven thalamic neurons that responded to electrical, mechanical and chemical stimulation of the contralateral dura were classified as trigeminovascular neurons [24]. Twenty-four of these neurons were successfully injected with TMR, yielding a detailed, high-resolution labeling of the cell body (seen in 1 or 2 sections), dendritic tree and proximal segment of the parent axon (extending over 5–6 sections) within the thalamus. In each of these cases, attempts were made to co-label the brain sections containing the TMR-positive trigeminovascular neurons with a different neuropeptide/neurotransmitter. Eighteen cases yielded successful labeling of both trigeminovascular neurons (TMR) and axons stained for markers of glutamate (n = 2), GABA (n = 2), serotonin (n = 3), noradrenaline (n = 2), dopamine (n = 3), histamine (n = 2), orexin (n = 2), MCH (n = 2), CGRP (n = 2), 5HT1D receptor (n = 2), oxytocin (n = 1) and vasopressin (n = 1).

Immunofluorescent labeling of thalamic trigeminovascular neurons by the spinal trigeminal (SpV) and the reticular thalamic nucleus (RT)

Glutamatergic innervations. Glutamatergic innervation was determined using vesicular glutamate transporter 2 (VGluT2) (Fig. 2). Axons immunoreactive to VGluT2, thus containing the excitatory neurotransmitter glutamate, were present at high density in all thalamic nuclei known to contain trigeminovascular neurons including ventral posterior medial (VPM), posterior (Po), lateral posterior (LP) and laterodorsal (LD). When examined in sections containing the trigeminovascular neuron(s), dense VGluT2 immunopositive vesicles were seen in close apposition to the cell body, proximal and distal dendrites (Fig. S1).

GABAergic innervations. GABAergic innervation was determined using vesicular GABA transporter (VGAT) (Fig. 3). Axons immunoreactive to VGAT, thus containing the inhibitory neurotransmitter GABA, were present at high density in all thalamic nuclei known to contain trigeminovascular neurons. When examined in sections containing the trigeminovascular neuron(s), denseVGAT immunopositive vesicles were seen in close apposition to the cell body, proximal and distal dendrites (Fig. S2).

Brainstem innervation of thalamic trigeminovascular neurons

Serotonergic innervations. Serotonergic innervation was determined using serotonin transporter (SERT) (Fig. 4), a stable marker of serotonergic fibers in the brain [27]. Axons immunoreactive to SERT, thus containing the monoamine neurotransmitter serotonin, were present at high density in all thalamic nuclei known to contain trigeminovascular neurons. When examined in sections containing the trigeminovascular neuron(s), dense SERT immunopositive axons and varicosities were seen in close apposition to the cell body, proximal and distal dendrites (Fig. 5).

Noradrenergic innervations. Noradrenergic innervation was determined using the enzyme dopamine β-hydroxylase (DBH) (Fig. 6). Axons immunoreactive to DBH, thus containing the catecholamine neurotransmitter noradrenaline, were present at moderate-to-high density in all thalamic nuclei known to contain trigeminovascular neurons. When examined in sections containing the trigeminovascular neuron(s), moderate density of DBH immunopositive axons and varicosities were seen in close apposition to the cell body, proximal and distal dendrites (Fig. S3). These DBH axons originate in the locus coeruleus, the main producer of noradrenaline in the brain.

Hypothalamic innervation of thalamic trigeminovascular neurons

Dopaminergic innervations. Dopaminergic innervation was determined using the enzyme tyrosine hydroxylase (TH) (Fig. 7). Axons immunoreactive to TH, thus containing the catecholamine

Modulation of Thalamic Trigeminovascular Neurons
neurotransmitter dopamine, were present at high density in all thalamic nuclei known to contain trigeminovascular neurons. When examined in sections containing the trigeminovascular neuron(s), high density of TH immunopositive axons and varicosities were seen in close apposition to proximal and distal dendrites (Fig. S4). Because TH is present in noradrenergic and dopaminergic cells, the interpretation of its labeling must take into consideration these two neurotransmitters. We interpreted some of the TH-positive axons as dopaminergic based on a recent retrograde tracing study where we showed that the dopaminergic cells group A11/A13 project to the same Po and LP areas in which trigeminovascular neurons were labeled in the current study [28].

**Histaminergic innervations.** (Fig. 8). Axons immunoreactive to histamine neurotransmitter were present at moderate density in LP and LD, and lower density in VPM and Po. When examined in sections containing the trigeminovascular neuron(s), moderate density of histaminergic immunopositive axons and varicosities were seen in close apposition to the cell body, proximal and distal dendrites (Fig. S5). This histaminergic innervation

![Figure 2. Glutamatergic innervation of thalamic trigeminovascular neurons.](image)

Left: Immunopositive VGluT2 synaptic vesicles (green) surrounding a thalamic dura-sensitive neuron (red) labeled with TMR–dextran. Arrowheads indicate close apposition of VGluT2 positive axons and the cell body and dendrites of the labeled neuron. Upper right: Location of the dura-sensitive neuron (red star) shown at left. Number in red indicates distance from bregma (mm). Lower right: Fluorescent images showing VGluT2 axonal labeling in thalamic Po and VPM nuclei. Scale bars = 100 μm. Abbreviations: DLG, dorsal lateral geniculate; LPMR, lateral posterior thalamic, mediorostral; LPLR, lateral posterior thalamic, laterorostral part; VPL, ventral posterolateral thalamic.

doi:10.1371/journal.pone.0103929.g002

![Figure 3. GABAergic innervation of thalamic trigeminovascular neurons.](image)

Left: Immunopositive VGaT synaptic vesicles (green) surrounding a thalamic dura-sensitive neuron (red) labeled with TMR–dextran. Nuclear counterstaining was performed with DAPI (blue). Arrowheads indicate close apposition of VGaT positive axons and the cell body and dendrites of the labeled neuron. Upper right: Location of the dusa-sensitive neuron (red star) shown at left. Number in red indicates distance from bregma (mm). Lower right: Fluorescent images showing VGaT axonal labeling in thalamic Po and VPM nuclei. Scale bars = 100 μm. Abbreviations: eml, external medullary lamina; ic, internal capsule; ZI, zona incerta.

doi:10.1371/journal.pone.0103929.g003
originates in the dorsal and ventral tuberomammillary nuclei of the hypothalamus, the sole producers of histamine in the brain.

**MCH innervations.** (Fig. 9) Axons immunoreactive to MCH were present at low density in all thalamic nuclei known to contain trigeminovascular neurons. When examined in sections containing the trigeminovascular neuron(s), low density of MCH immunopositive axons and varicosities were seen in close apposition only to distal dendrites (Fig. S6). These MCH axons originate mainly in the lateral hypothalamus.

**Orexinergic innervations.** Orexinergic innervation was determined by targeting the neuropeptide orexin A (Fig. 10). Axons immunoreactive to orexin A were present at low density in LP, LD, Po and VPM. When examined in sections containing the trigeminovascular neuron(s), low density of orexinergic immunopositive axons and varicosities were seen in close apposition to the proximal and distal dendrites, but not the cell body (Fig. S7). These orexinergic axons originate mainly in the perifornical hypothalamic area.

**Thalamic trigeminovascular neurons are not innervated by CGRP, 5HT1D, oxytocin or vasopressin**

Surprisingly, we found no evidence for presence of CGRP-positive axons in any thalamic nucleus containing trigeminovascular neurons (positive identification of CGRP fibers in the parvicellular division of the ventral posterior thalamic nucleus confirms the validity of the negative staining in the thalamic nuclei analyzed in this study) (Fig. 11A). Similarly, we found no evidence for presence of 5HT1D receptors in the relevant thalamic nuclei. Positive identification of 5HT1D afferents in the medullary dorsal horn confirms the validity of the negative staining in the thalamic nuclei analyzed in this study (Fig. 11B). Predictably, we also found no evidence for innervation of thalamic trigeminovascular neurons by oxytocin or vasopressin from neurons in the paraventricular or supraoptic hypothalamic nuclei (Figs. 11C–D), demonstrating the selectivity of the positive findings.

**Density of thalamic innervation by the different biomarkers**

We processed all images containing immunohistochemical evidence for thalamic innervation of the neurotransmitter/neuropeptides, and calculated their relative density by using binary maps (ImageJ). The binary map identifies all pixels containing positive immunostaining and converts them to white pixels; the remaining black pixels are considered lack of staining. This data provide quantitative measures of density of innervation of thalamic areas where juxtaacellularly labeled trigeminovascular neurons were found (Table 1 and Figs. S8 and S9).

**Discussion**

This proof-of-concept study defines a new molecular framework for a more sophisticated thinking of the complexity of factors that modulate the response properties of relay trigeminovascular thalamic neurons. Most significant was the finding that such neurons receive direct input from axons containing glutamate, GABA, dopamine, noradrenaline, serotonin, histamine, orexin and MCH but not from axons that contain oxytocin, vasopressin, CGRP or the 5HT1D receptor (Fig. 12A). This diverse input suggests that the transmission of headache-related nociceptive signals from the thalamus to the cortex is modulated by potentially opposing forces and that the so-called ‘decision’ of which system (neuropeptide/neurotransmitter) will dominate the firing of a trigeminovascular thalamic neuron at any given time is determined by the constantly changing physiological (sleep, wakefulness, food intake, body temperature, heart rate, blood pressure), behavioral (addiction, isolation), cognitive (attention, learning, memory use) and affective (stress, anxiety, depression, anger) adjustment needed to keep homeostasis (Fig. 12B).

The discharge mode of relay thalamocortical neurons is either burst or tonic [1,29]. The burst discharge is commonly associated with lower excitability, drowsiness, and in the context of headache, responses to acute pain, whereas the tonic discharge has been associated with higher excitability, wakefulness, and chronic pain.
In principle, each of the neurotransmitters/neuropeptides found in this study to have close apposition with thalamic trigeminovascular neurons can potentially shift their firing mode from burst to tonic if it is excitatory, and from tonic to burst if it is inhibitory. As in other systems, the action of each neuropeptide/neurotransmitter on individual thalamic neuron depends on the type of release and reuptake, the type of receptor activated, and most likely the location of the neuron and its projection targets in the cortex. Since this information is not available for thalamic trigeminovascular neurons, which are the subject of this study, speculation on possible roles of the identified neuropeptides/neurotransmitters in setting thalamic transmission, as it may be related to migraine headache, is based on their known action in other systems.

**Glutamate**

Vesicular glutamate transporters (VGluTs) are responsible for glutamate trafficking and for the subsequent regulated release of this excitatory neurotransmitter at the synapse. Glutamate excites relay thalamocortical neurons through NMDA receptors, if the sensory stimulus is brief [33,34]. Of the three isoforms of VGluT, we opted to study VGluT2 because it is expressed most densely in relay thalamic nuclei [35–39] and in ascending trigeminal sensory neurons that project to VPM and Po [40,41]. Since VGluT1 axons originate in corticothalamic neurons, we interpreted the presence of VGluT2 on thalamic trigeminovascular neurons as constituting the main drive for activation of these neurons by glutamatergic input they receive from ascending trigeminothalamic (possibly dura-sensitive) neurons in SpV.

**Dopamine**

In the context of migraine, dopamine has been considered for its role in promoting hypothalamic-mediated symptoms/prodromes such as yawning and nausea [42], and more recently, modulation of dorsal horn trigeminovascular neurons [43]. Further supporting this hypothalamic connection is the finding that the A11 dopaminergic cell group in the medial hypothalamus innervates trigeminovascular neurons in both, the medullary dorsal horn [44,45] and the thalamic relay nuclei [28]. The rich innervation of thalamic trigeminovascular neurons by TH-positive fibers suggests that modulation of transmission of nociceptive trigeminovascular...
signals by dopamine may also occur at the thalamus. When conceptualizing dopamine role in migraine, a consideration should be given to the activation of thalamic D₁ and D₂ receptors which facilitate membrane depolarization and increase spike discharge in somatosensory VPL/VPM thalamic neurons [46], and to the selective uptake of cocaine by dopaminergic nerve terminals in the thalamus as these findings define the possibility that thalamic dopamine pathways may be critically involved in drug-addiction, impulse control, affect, attention and decision making [47–53]. Translating these into clinical implications, thalamic dopamine may thus be considered as a possible contributor to behaviors that lead to medication-overuse headache and exacerbation of headache by negative emotions, effort to control anger and irritability, cognitive tasks that require attention and the need to make mundane decisions.

Serotonin

Relevant to this study is that serotonin has long been implicated in migraine pathophysiology [54,55], that this implication has lead to the development of 5HT₁B/₁D receptor agonists (i.e., triptans).
for acute treatment of migraine, that serotonergic innervation of VPM and Po originating mainly in the rostral raphe [9,56–59], and that depending on the amount of serotonin release in the thalamus, it could be facilitatory (at low concentration) or inhibitory (at high concentration) to relay neurons in VPM and Po [60]. In principle, a high concentration of serotonin is inhibitory whereas a low concentration is excitatory. Accordingly, the very dense innervation of thalamic trigeminovascular neurons observed in our study can provide an anatomical substrate for a predominantly inhibitory effect of serotonin on transmission of trigeminovascular information between the thalamus and the cortex, as well as the inhibition of trigeminovascular thalamic neurons by local administration of 5HT1 agonists [61]. Given the latter, we were surprised by the total absence of 5HT1D receptors in the thalamus. This finding suggests that the inhibition of thalamic trigeminovascular neurons response to dural stimulation occur at an earlier synapse along the trigeminovascular pathway [62], rather than in the thalamus. On a more global view, serotonin, through its involvement in stress [63], anxiety [64], depression [65], sleep [66], apetite [67], and learning [64] may help facilitate the reciprocal relationship between these affective and physiological states and migraine.

**Figure 8. Histaminergic innervation of thalamic trigeminovascular neurons.** Left: Immunopositive Histamine axons (green) surrounding a thalamic dura-sensitive neuron (red) labeled with TMR–dextran. Nuclear counterstaining was performed with DAPI (blue). Arrowheads indicate close apposition of Histamine positive axons and the cell body and dendrites of the labeled neuron. Upper right: Location of the dura-sensitive neuron (red star) shown at left. Number in red indicates distance from bregma (mm). Lower right: Fluorescent image showing Histamine labeling of cell bodies in the dorsal and ventral tuberomammillary nuclei of the hypothalamus (DTM and VTM). Scale bars = 100 μm.

doi:10.1371/journal.pone.0103929.g008

**Figure 9. MCH innervation of thalamic trigeminovascular neurons.** Left: Immunopositive Melanin Concentrating Hormone axons (green) surrounding a thalamic dura-sensitive neuron (red) labeled with TMR–dextran. Nuclear counterstaining was performed with DAPI (blue). Arrowheads indicate close apposition of MCH positive axons and the dendrites of the labeled neuron. Upper right: Location of the dura-sensitive neuron (red star) shown at left. Number in red indicates distance from bregma (mm). Lower right: Fluorescent image showing MCH labeling of cell bodies in the lateral hypothalamus (LH). Scale bars = 100 μm. Abbreviations: ZID, zona incerta, dorsal; ZIV, zona incerta, ventral.

doi:10.1371/journal.pone.0103929.g009
Noradrenaline

Because of the wide distribution of noradrenergic fibers in the brain it is difficult to assign to this neurotransmitter a specific role in certain function. Rather, it is thought to improve signal-to-noise ratio in the firing of neurons that respond to sensory stimuli [11,68–70] when conditions involve anticipation, reward, and...

Figure 10. Orexinergic innervation of thalamic trigeminovascular neurons. Left: Immunopositive Orexin A axons (green) surrounding a thalamic dura-sensitive neuron (red) labeled with TMR-dextran. Nuclear counterstaining was performed with DAPI (blue). Arrowheads indicate close apposition of OrA positive axons and the dendrites of the labeled neuron. Upper right: Location of the dura-sensitive neuron (red star) shown at left. Number in red indicates distance from bregma (mm). Lower right: Fluorescent image showing OrA labeling of cell bodies in the hypothalamic perifornical area (PeF). Scale bars = 100 µm. Abbreviation: LDVL, laterodorsal thalamic, ventrolateral.
doi:10.1371/journal.pone.0103929.g010

Figure 11. Lack of innervation of thalamic trigeminovascular neurons by axons containing CGRP, Serotonin 1D receptor, Oxytocin and Vasopressin. Left A–D: Thalamic dura-sensitive neurons (red) labeled with TMR-dextran and nuclear counterstain with DAPI (blue). Note the absence of axonal immunoreactivity to CGRP (A), Serotonin 1D receptor (B), Oxytocin (C) and Vasopressin (D). Upper right A–D: Locations of the dura-sensitive neurons (red stars) shown at left. Numbers in red indicate distance from bregma (mm). Lower right A–D: Fluorescent images showing CGRP (A) and Serotonin 1D receptor (B) immunopositive axons in the parvcellular division of the ventral posterior thalamic nucleus (VPpc) and the spinal trigeminal nuclei (SpVC/SpVI; caudal/interpolar), respectively. Lower right C: Fluorescent images showing Oxytocin labeling of cell bodies and axons in the hypothalamic paraventricular nucleus (PVN) and lateral hypothalamus (LH), respectively. Lower right D: Fluorescent images showing Vasopressin labeling of cell bodies in the PVN and circular (Cir) nuclei of the hypothalamus, and axons in the LH. Scale bars = 100 µm.
doi:10.1371/journal.pone.0103929.g011
changing cognitive and emotional circumstances [71]. To be in a position to modulate thalamic neurons, noradrenergic fibers project heavily to all thalamic sensory nuclei [72,73] and act on both α and β adrenoceptors, which together modulate firing rate, set a pacemaker current, determine membrane resting potential, and synaptic strength [74–77]. In the context of migraine, noradrenaline, which usually prolongs the activation of thalamic neurons [78–81], may be involved in setting abnormal excitability level in trigeminovascular neurons, centrally, and the magnitude of arterial hypertension, peripherally. This view is supported by the finding that β1 adrenoceptor blockers, which are among the very few drugs approved as migraine prophylactics [82], inhibit the activity of thalamic trigeminovascular neurons [83]. The observed relationship between noradrenergic fibers and thalamic trigemino-vascular neurons suggest that histaminergic nerve terminals converge on thalamic trigeminovascular neurons [83]. 

Histamine

In the context of migraine, histamine has been considered for its role in causing H1 receptor mediated arterial dilatation and the consequential induction of delayed headache [84]. The findings that histaminergic nerve terminals converge on thalamic trigeminovascular neurons suggest that histamine role in migraine may also include modulation of thalamic trigeminovascular neurons through excitatory H1 receptors whose action enhances slow depolarization current capable of switching neuronal discharge mode from burst to tonic [85]. In the CNS, histamine originates exclusively from neurons of the tuberomammillary hypothalamic nucleus [17,18]. Given that these neurons are active during the wake-state and quiescent during the sleep state [86–88] and that histamine switches the firing mode of relay thalamic neurons from burst to tonic [3,85], it is tempting to speculate that the modulation of thalamic trigeminovascular neurons by the histaminergic pathway may play a role in the partial, or even complete, headache relief provided by sleep.

Melanin Concentrating Hormone

The MCH system, which originates in the hypothalamus and contains GABA [89] is thought to play a modulatory/inhibitory role in the regulation of energy expenditure, arousal, locomotion, sexual behavior and a variety of autonomic functions [90–94]. Being excited by increased glucose level after a meal, MCH neurons are thought to promote sleep and energy expenditure (i.e., cessation of food intake) by releasing GABA at multiple cortical, subcortical, brainstem and spinal areas they project to. To date, this system has not been considered in the pathophysiology of migraine or other headaches. The findings that hypothalamic MCH neurons issue axons that terminate on thalamic trigeminovascular neurons define a novel anatomo-functional substrate for hypothesizing about possible interactions between food intake, drowsiness and migraine. It is tempting to propose that the mechanism by which eating may make patients ‘feel better’ during migraine involves increased level of glucose, activation of hypothalamic MCH neurons [95], and the consequential inhibition of relay thalamic trigeminovascular neurons. Conversely, this anatomo-functional substrate may also explain a part of the reasons for why migraine is promoted by skipping a meal. Skipping a meal inhibits MCH neurons (as glucose level goes down) that, when inactive, may release far less GABA around thalamic trigeminovascular neurons. Reduced GABA input might then enhance neuronal excitability, rendering them more likely to respond to subthreshold input they receive from ascending dural-sensitive neurons in the spinal trigeminal nucleus.

Orexin

The orexin system originates in the lateral hypothalamus (LH) and projects to the cortex, thalamus, brainstem, spinal cord and other hypothalamic nuclei [20,96–99]. It consists of 2 neuropeptides (orexin A, orexin B) that are synthesized by the same gene [100] and act on 2 classes of receptors, the selective orexin receptor 1 (orexin A) and the non-selective orexin receptor 2 (orexin A and B). The wide distribution of orexin fibers in the brain support a role in regulating food intake, arousal, wakefulness

Table 1. Relative density of thalamic innervation by neurotransmitters and neuropeptides.

| neurotransmitter/neuropeptide | Positive Pixels | Negative Pixels | Positive Pixels (%) | Density |
|-----------------------------|----------------|----------------|---------------------|---------|
| VGluT2                      | 139,571        | 1,308,109      | 9.64                | High    |
| TH                          | 124,675        | 1,323,005      | 8.61                | High    |
| VGaT                        | 106,398        | 1,341,282      | 7.35                | High    |
| SERT                        | 82,190         | 1,365,490      | 6.58                | High    |
| DBH                         | 46,331         | 1,401,349      | 3.20                | Moderate|
| Hist                        | 17,578         | 1,430,102      | 1.21                | Moderate|
| Orexin                      | 8,555          | 1,439,125      | 0.59                | Low     |
| MCH                         | 7,153          | 1,440,527      | 0.49                | Low     |
| CGRP                        | 0              | 1,447,680      | 0.0                 | Absent  |
| SHT1D                       | 0              | 1,447,680      | 0.0                 | Absent  |
| Vaso                        | 0              | 1,447,680      | 0.0                 | Absent  |
| Oxy                         | 0              | 1,447,680      | 0.0                 | Absent  |

Quantitative analysis using binary maps: >5% of positive (white) pixels per image indicates high density, 1–5% indicates moderate density, and <1% indicates low density of innervation. See Figs. S8 and S9 for actual binary maps. doi:10.1371/journal.pone.0103929.t001
and sympathetically-mediated increase in body temperature, heart rate and blood pressure [101]. Opposite to the function of the MCH system, orexin neurons are excited by falling glucose levels, and their activation promotes food intake and wakefulness [102–104]. Of potential relevance to the pathophysiology of migraine are orexinergic axons in nociceptive laminae of the medullary dorsal horn and in close apposition to thalamic trigeminovascular neurons. Although no information is available regarding the direction in which orexin modulates thalamic trigeminovascular neurons, in vitro slice recording of thalamic neurons suggests that both orexin B and, for a lesser extent, orexin A are capable of depolarizing these neurons sufficiently to switch their firing from the sleep-associated burst mode to the wakefulness-associated tonic mode [105]. In the context of migraine, it is thus reasonable to hypothesize that the mechanism by which eating may reduce headache intensity involves not only local release of GABA from activated MCH neurons but also inhibition of facilitatory orexin input to thalamic trigeminovascular neurons induced by increased glucose level (orexin neurons are inhibited by glucose). And conversely, fasting-induced fall in glucose activates the orexinergic neurons which in turn facilitate excitability through local release of orexin B and A.

Calcitonin Gene Related Peptide

A large number of studies suggest that CGRP plays an important role in multiple aspects of migraine pathophysiology [106]. Of particular relevance to the current study is the Summ et al., paper [107] demonstrating presence of CGRP receptors in VPM and consequently, inhibition of thalamic trigeminovascular neurons by systemic and local administration of CGRP receptor antagonists. The absence of CGRP-positive fibers in the vicinity of thalamic trigeminovascular neurons suggests that CGRP release is not localized within the thalamus but rather may be released at a distant location of the receptors, acting as a neurohormone.

The thalamus is intricately connected with multiple cortical, subcortical and brainstem regions. It is viewed as an important subcortical hub with respect to functional brain networks [108] involved in processes that are altered in certain disease states [109,110]. In the migraine brain, changes in modulation of...
thalamic neurons by various inputs may have significant effects on thalamic functional connectivity during both the interictal and the ictal state. The diverse neurochemical pathways that converge on thalamic trigeminovascular neurons (Fig. 12A–B) and the probability that many of them modulate neuronal activity in the same direction under certain conditions (e.g., sleep deprivation) and in opposite directions under other conditions (e.g., when satiated or scared) define a sophisticated neuroanatomical network that may help us conceptualize how sensory, physiological, cognitive and affective conditions trigger, worsen or improve migraine headache.

Supporting Information

Figure S1 Close apposition between VGluT2 immunopositive vesicles and thalamic trigeminovascular neurons. The three views in the x–y, y–z and x–z planes provide evidence that VGluT2 immunopositive vesicles (green) may contact cell bodies, proximal and distal dendrites of trigeminovascular neurons in LP (red; as shown in Fig. 2). Arrowheads indicate probable contact point on each view. Note that some green-labeled vesicles and red-labeled soma or dendrites are in the same focal plane (yellow). Scale bar = 50 μm.

Figure S2 Close apposition between VGaT immunopositive vesicles and thalamic trigeminovascular neurons. The three views in the x–y, y–z and x–z planes provide evidence that VGaT immunopositive vesicles (green) may contact cell bodies, proximal and distal dendrites of trigeminovascular neurons in PVM (red; as shown in Fig. 3). Arrowheads indicate probable contact point on each view. Note that some green-labeled vesicles and red-labeled soma or dendrites are in the same focal plane (yellow). Scale bar = 50 μm.

Figure S3 Close apposition between DBH immunopositive axons and thalamic trigeminovascular neurons. The three views in the x–y, y–z and x–z planes provide evidence that DBH immunopositive fibers (green) may contact cell bodies, proximal and distal dendrites of trigeminovascular neurons in Po (red; as shown in Fig. 6). Arrowheads indicate probable contact point on each view. Note that some green-labeled axons and red-labeled soma or dendrites are in the same focal plane (yellow). Scale bar = 50 μm.

Figure S4 Close apposition between TH immunopositive axons and thalamic trigeminovascular neurons. The three views in the x–y, y–z and x–z planes provide evidence that TH immunopositive fibers (green) may contact proximal and distal dendrites of trigeminovascular neurons in Po (red; as shown in Fig. 7). Arrowheads indicate probable contact point on each view. Note that some green-labeled axons and red-labeled dendrites are in the same focal plane (yellow). Scale bar = 50 μm.

Figure S5 Close apposition between Histamine immunopositive axons and thalamic trigeminovascular neurons. The three views in the x–y, y–z and x–z planes provide evidence that Histamine immunopositive fibers (green) may contact cell bodies, proximal and distal dendrites of trigeminovascular neurons in LP (red; as shown in Fig. 8). Arrowheads indicate probable contact point on each view. Note that some green-labeled axons and red-labeled soma or dendrites are in the same focal plane (yellow). Scale bar = 50 μm.

Figure S6 Close apposition between MCH immunopositive axons and thalamic trigeminovascular neurons. The three views in the x–y, y–z and x–z planes provide evidence that MCH immunopositive fibers (green) may contact distal dendrites of trigeminovascular neurons in VPM (red; as shown in Fig. 9). Arrowheads indicate probable contact point on each view. Note that some green-labeled axons and red-labeled dendrites are in the same focal plane (yellow). Scale bar = 50 μm.

Figure S7 Close apposition between Orexin A immunopositive axons and thalamic trigeminovascular neurons. The three views in the x–y, y–z and x–z planes provide evidence that Orexin A immunopositive fibers (green) may contact proximal and distal dendrites of trigeminovascular neurons in LD (red; as shown in Fig. 10). Arrowheads indicate probable contact point on each view. Note that some green-labeled axons and red-labeled dendrites are in the same focal plane (yellow). Scale bar = 50 μm.

Figure S8 Density maps of thalamic innervation by neurotransmitters and neuropeptides. Left: photomicrographs showing immunofluorescence staining of each biomarker in thalamic areas where juxtacellularly labeled trigeminovascular neurons were recorded (for anatomical reference, see figures 2–6). Right: Binary heat maps obtained from the images on the left showing all pixels (in red) containing positive immunostaining. Based on this data, objective measures to quantify density of innervation were obtained and defined as follow: High: ≥5% of positive pixels per image; Moderate: 1–5%; Low: <1%. The relative density of innervation by VGluT2, VGaT, SERT, DBH is 9.64% (high), 7.35% (high), 5.68% (high) and 3.2% (moderate) of positive pixels, respectively. Scale bar = 100 μm.

Figure S9 Density maps of thalamic innervation by neurotransmitters and neuropeptides. Left: photomicrographs showing immunofluorescence staining of each biomarker in thalamic areas where juxtacellularly labeled trigeminovascular neurons were recorded (for anatomical reference, see figures 7–10). Right: Binary heat maps obtained from the images on the left showing all pixels (in red) containing positive immunostaining. The relative density of innervation by TH, Histamine, Orexin and MCH is 8.61% (high), 1.21% (moderate), 0.59% (low) and 0.49% (low) of positive pixels, respectively. Scale bar = 100 μm.

Author Contributions

Conceived and designed the experiments: RN RB. Performed the experiments: RN VK. Analyzed the data: RN VK DB RB. Wrote the paper: RN DB RB.

References

1. Sherman SM (2000) Thalamic relays and cortical functioning. Prog Brain Res 149: 107–126.
2. Sherman SM, Guillery RW (1998) On the actions that one nerve cell can have on another: Distinguishing “drivers” from “modulators”. Proceedings of the National Academy of Sciences of the United States of America 95: 7121–7126.
3. McCormick DA (1992) Neurotransmitter actions in the thalamus and cerebral cortex and their role in neuromodulation of thalamocortical activity. Prog Neurobiol 39: 337–388.
4. Steriade M, McCormick DA, Sejnowski TJ (1993) Thalamocortical oscillations in the sleeping and aroused brain. Science 262: 679–685.
32. McCormick DA, Bal T (1997) Sleep and arousal: thalamocortical mechanisms. Proc Natl Acad Sci U S A 89: 2774–2778.

31. Steriade M, Domich L, Oakson G (1986) Reticularis thalami neurons revisited: a somatotopic and noradrenergic projection to the ventral posterolateral nucleus of the monkey thalamus. J Comp Neurol 295: 197–207.

28. Kagan R, Kainz V, Burstein R, Noseda R (2013) Hypothalamic and basal forebrain regulation of thalamic neurons in vivo. J Physiol 591: 581–99.

27. Nielsen K, Brask D, Knudsen GM, Aznar S (2006) Immunodetection of the t-NT component of the NT/NE complex in the rat raphe nucleus. J Neurosci 26: 1367–1375.

26. Paxinos G, Watson C (2008) The Rat Brain in Stereotaxic Coordinates: 3rd edn. Academic Press.

25. Pinault D (1996) A novel single-cell staining procedure performed in vivo by intracellular injection of biocytin. J Neurosci Methods 65: 113–136.

24. Adamantidis A, de Lecea L (2009) A role for Melanin-Concentrating Hormone (MCH) and its receptors in the control of food intake. Physiol Rev 89: 73–117.

23. Bittencourt JC, Frigo L, Rissman RA, Casatti CA, Nahon JL, et al. (1998) The ventral tegmental area projects to the intrathalamic nuclei and is influenced by orexin (hypocretin) neurons. J Neurosci 18: 4028–4039.

22. Morrison JH, Foote SL (1986) Noradrenergic and serotoninergic innervation of the amygdala. J Comp Neurol 243: 117–138.

21. Bittencourt JC, Frigo L, Rissman RA, Casatti CA, Nahon JL, et al. (1998) The ventral tegmental area projects to the intrathalamic nuclei and is influenced by orexin (hypocretin) neurons. J Neurosci 18: 4028–4039.

20. Nambu T, Sakurai T, Mizukami K, Hosoya Y, Yanagisawa M, et al. (1999) Expression of orexin A and B in the rat brain. Brain Res Mol Brain Res 65: 14204–14217.

19. Sakurai T (2007) The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Brain Res 1138: 5–12.

18. Panula P, Pirvola U, Auvinen S, Airaksinen MS (1989) Histamine-neuronal transmission in the mammalian brain. Physiol Rev 71: 1–51.

17. Schwartz JC, Arrang JM, Garbarg M, Pollard H, Ruat M (1991) Histaminergic neurones projecting to the spinal cord: Possible role in modulation of nociception. Brain Res Rev 16: 49–62.

16. Garcia-Cabezas MA, Martinez-Sanchez P, Sanchez-Gonzalez MA, Cavada C (2007) Distribution of the dopamine and norepinephrine innervation in the thalamus. Neuroscience 14204–14217.

15. Garcia-Cabezas MA, Rico B, Sanchez-Gonzalez MA, Garzon M, Cavada C (2009) Dopaminergic innervation in the thalamus: monkey versus rat. Cereb Cortex 19: 424–434.

14. Schwartz JC, Arrang JM, Garbarg M, Pollard H, Ruat M (1991) Histaminergic neurones projecting to the spinal cord: Possible role in modulation of nociception. Brain Res 16: 49–62.

13. Groenewegen HJ (1988) Organization of the afferent connections of the lateral geniculate nucleus of the cat. J Comp Neurol 243: 193–223.

12. McCallum KA, Groenewegen HJ (1987) Afferent connections of the lateral geniculate nucleus of the cat. J Comp Neurol 243: 193–223.

11. Morrison JH, Foote SL (1986) Noradrenergic and serotoninergic innervation of the amygdala. J Comp Neurol 243: 117–138.

10. Papadopoulos GC, Parnavelas JG (1990) Distribution and synaptic organization of dopaminergic axons in the lateral geniculate nucleus of the rat. J Comp Neurol 294: 345–355.

9. Westlund KN, Sorkin LS, Ferrington DG, Carlton SM, Willcockson HH, et al. (1986) Serotonergic projections to the neocortex and thalamus: distribution of serotonin-immunoreactive nerves in monkey brain. Neuroscience 20: 385–610.

8. Sanchez-Gonzalez MA, Garcia-Cabezas MA, Rico B, Cavada C (2005) The primate thalamus is a key target for brain dopamine. J Neurosci 25: 6076–6083.

7. Nielsen K, Brask D, Knudsen GM, Aznar S (2006) Immunodetection of the t-NT component of the NT/NE complex in the rat raphe nucleus. J Neurosci Methods 65: 113–136.

6. Sherman SM, Guillery RW (1996) Functional organization of thalamocortical relays. J Neurophysiol 76: 1367–1395.

5. Guillery RW, Sherman SM (2002) Thalamic relay functions and their role in corticothalamic communication: generalizations from the visual system. J Neurophysiol 86: 133–167.

4. Sherman SM, Guillery RW (1996) Functional organization of thalamocortical relays. J Neurophysiol 76: 1367–1395.

3. Steriade M, Domich L, Oakson G (1986) Reticularis thalami neurons revisited: a somatotopic and noradrenergic projection to the ventral posterolateral nucleus of the monkey thalamus. J Comp Neurol 295: 197–207.

2. Papadopoulos GC, Parnavelas JG (1990) Distribution and synaptic organization of dopaminergic axons in the lateral geniculate nucleus of the rat. J Comp Neurol 294: 356–361.

1. Groenewegen HJ (1988) Organization of the afferent connections of the medial thalamic nucleus in the rat, related to the midline-dorsal medial-prefrontal projection. Neurosci 24: 379–413.

This page contains a list of scientific references related to thalamic trigeminovascular neurons. The references cover a wide range of topics, including the anatomy, physiology, and pharmacology of these neurons. The study of thalamic trigeminovascular neurons is important for understanding the mechanisms underlying headache and other sensory disorders. The references cite studies that have used various experimental methods, such as immunohistochemistry, electrophysiology, and pharmacology, to investigate the roles of these neurons in pain modulation and synaptic plasticity. The references also discuss the involvement of different neurotransmitters and neuromodulatory systems in the regulation of thalamic trigeminovascular neurons. This page is part of a larger document that provides a comprehensive overview of the field, and it is likely to be useful for researchers and students interested in this area of neuroscience.
66. Green AR (2006) Neuropharmacology of 5-hydroxytryptamine. Br J Pharma-
col 147 Suppl 1: S145–152.
67. Yeo GS, Hepler LD (2012) Unraveling the brain regulation of appetite: lessons
from genetics. Nat Neurosci 13: 1349–1349.
68. Eggo-Stengel V, Briuguer V, Shulze DE (2002) Noradrenergic modulation of
functional selectivity in the cat visual cortex: an in vivo extracellular and
intracellular study. Neuroscience 111: 275–289.
69. Devibhui DS, Waterhouse BD (2004) The effects of tonic locus ceruleus output
on sensory-evoked responses of ventral posterior medial thalamic and barrel
field cortical neurons in the awake rat. J Neurosci 24: 10773–10785.
70. Berriidge CW, Schmeichel BE, Espana RA (2012) Noradrenergic modulation of
wakefulness/arousal. Sleep Med Rev 16: 187–197.
71. Berriidge CW, Waterhouse BD (2003) The locus coeruleus-noradrenergic sys-
ystem: modulation of behavioral state and state-dependent cognitive processes.
Brain Res Brain Res Rev 42: 33–84.
72. Linnvall O, Bjorklund A, Nobin A, Stenevi U (1974) The adrenergic innerva-
tion of the rat thalamus as revealed by the glyoxylic acid fluorescence
method. J Comp Neurol 154: 317–347.
73. De Lima AD, Singer W (1987) The brainstem projection to the lateral
geniculate nucleus in the cat: identification of cholinergic and monoaminergic
elements. J Comp Neurol 259: 92–121.
74. Pepe HC, McCormick DA (1980) Noradrenaline and serotonin selectively
modulate thalamic burst firing by enhancing a hyperpolarization-activated
cation current. Nature 340: 715–718.
75. Luthi A, McCormick DA (1998) Periodicity of thalamic synchronized
cation current. Nature 340: 715–718.
76. Luthi A, McCormick DA (1998) H-current: properties of a neuronal and
network pacemaker. Neuron 21: 9–12.
77. Robinson RB, Siegelbaum SA (2003) Hyperpolarization-activated cation
currents: from molecules to physiological function. Annu Rev Physiol 65:
435–480.
78. Rogawski MA, Agajanian GK (1990) Noradrenaline and serotonin: opposite
effects on the activity of lateral geniculate neurons evoked by optic pathway
stimulation. Exp Neurol 90: 678–694.
79. Rogawski MA, Agajanian GK (1980) Modulation of lateral geniculate
genue excitability by noradrenaline microiontophoresis or locus coeruleus
stimulation. Nature 287: 731–734.
80. Kayama Y, Negi T, Sugitani M, Iwama K (1982) Effects of locus coeruleus
stimulation on neuronal activities of dorsal lateral geniculate nucleus and
perigeniculate reticular nucleus of the rat. Neuroscience 7: 655–666.
81. Kayama Y (1985) Ascending, descending and local control of neuronal activity
in the rat lateral geniculate nucleus. Vision Res 25: 339–347.
82. Welch KM (1995) Drug therapy of migraine. N Engl J Med 332: 1476–1483.
83. Shields KG, Goadsby PJ (2005) Propranolol modulates trigeminovascular
responses in thalamic ventroposteromedial nucleus: a role in migraine? Brain
128: 86–97.
84. Krabbe AA, Olesen J (1980) Headache provocation by continuous intravenous
infusion of histamine. Clinical results and receptor mechanisms. Pain 8:
253–259.
85. McCormick DA, Williamson A (1994) Modulation of neuronal firing mode in
cat and guinea pig LGN by histamine: possible cellular mechanisms of histam-
ergic control of arousal. J Neurosci 11: 3188–3199.
86. Brown RE, Stevens DR, Haas HL (2001) The physiology of brain histamine.
Prog Neurobiol 63: 657–672.
87. Monit JM (1999) Involvement of histamine in the control of the waking state.
Life Sci 53: 1331–1338.
88. Lin JS, Sakai K, Jouvet M (1988) Evidence for histaminergic arousal
mechanisms in the hypothalamus of cat. Neuropharmacology 27: 111–122.
89. Elias CF, Lee CE, Kelly JF, Ahima RS, Kuhar M, et al. (2001) CART
neurons in the rat and human hypothalamus. J Comp Neurol 432: 1–19.
90. March DJ, Weingarth DT, Novi DE, Chen HY, Trombauer ME, et al. (2002)
Melanin-concentrating hormone 1 receptor-deficient mice are lean, hyperac-
tive, and hyperphagic and have altered metabolism. Proc Natl Acad Sci U S A
99: 3240–3245.
91. Hassani A, Lee MG, Jones BE (2009) Melanin-concentrating hormone
neurons discharge in a reciprocal manner to orexin neurons across the sleep-
wake cycle. Proc Natl Acad Sci U S A 106: 2418–2422.
92. Astrand A, Bohlooly YM, Larssdotter S, Maldalup M, Andersen H, et al. (2004)
Mice lacking melanin-concentrating hormone receptor 1 demonstrate
increased heart rate associated with altered autonomic activity. Am J Physiol
Regul Integr Comp Physiol 287: R749–758.
93. Gonzalez MI, Mazzi S, Wilson CA (1996) Behavioral effects of alpha-MSH and
MCH after central administration in the female rat. Peptides 17: 171–177.
94. Segal-Lieberman G, Bradley R, Kokkotou E, Carlson M, Trombly DJ, et al. (2005)
Melanin-concentrating hormone is a critical mediator of the leptin-
deficient phenotype. Proc Natl Acad Sci U S A 100: 10985–10990.
95. Burdakov D, Gerasimenko O, Verkhratsky A (2002) Physiological changes in
glucose differentially modulate the excitability of hypothalamic melanin-
concentrating hormone and orexin neurons in situ. J Neurosci 25: 2429–2433.
96. Peyron C, Tighe DK, van den Pol AN, de Lecea L, Heller HC, et al. (1998)
Neurons containing hypocretin (orexin) project to multiple neuronal systems.
J Neurosci 18: 9996–99915.
97. Elias CF, Saper CB, Maratos-Flier E, Tritos NA, Lee C, et al. (1998)
Chemically defined projections linking the medial basal hypothalamus and the
lateral hypothalamic area. J Comp Neurol 402: 442–459.
98. Date Y, Ueta Y, Yamashita H, Yamaguchi H, Matsuura S, et al. (1999)
Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuro-
endocrine and neuroregulatory systems. Proc Natl Acad Sci U S A 96: 748–
753.
99. Broberger C, De Lecea L, SueliFie GJ, Hokfelt T (1998) Hypocretin/orxin-
and melanin-concentrating hormone-expressing cells form distinct populations
in the rodent lateral hypothalamus: relationship to the neuropeptide Y and
agouti gene-related proteins systems. J Comp Neurol 402: 460–474.
100. Sakurai T, Amemiya A, Ishi M, Matsuaki I, Chenelli RM, et al. (1998)
Orexins and orexin receptors: a family of hypothalamic neuropeptides and G
protein-coupled receptors that regulate feeding behavior. Cell 92: 573–593.
101. Giraud EM, Yi CX, Fiers E, Kalsbeek A (2012) Orexins, feeding, and energy
balance. Prog Brain Res 198: 47–64.
102. Lampminger GM (2011) Lateral thinking about leptin: a review of leptin action
via the lateral hypothalamus. Physiol Behav 104: 572–581.
103. Yamamaka A, Beuckmann CT, Willie JT, Han J, Tsuino N, et al. (2003)
Hypothalamic orexin neurons regulate arousal according to energy balance in
mice. Neuron 38: 701–713.
104. Kelz MB, Sun Y, Chen J, Cheng Meng Q, Moore JT, et al. (2008) An essential
role for orexins in emergence from general anesthesia. Proc Natl Acad Sci U S A
105: 1309–1314.
105. Govindanah G, Cox CL (2006) Modulation of thalamic neuron excitability by
orexins. Neuropharmacology 51: 414–425.
106. Ho TW, Edvinsson L, Goadsbty PJ (2010) CGRP and its receptors provide new
insights into migraine pathophysiology. Nat Rev Neurol 6: 573–582.
107. Sunn O, Charbit AR, Androu AP, Goadsbty PJ (2010) Modulation of
nociceptive transmission with calcitonin gene-related peptide receptor
agonists in the thalamus. Brain 133: 2540–2548.
108. Tomasi D, Volkow ND (2011) Association between functional connectivity
hubs and brain networks. Cereb Cortex 21: 2003–2013.
109. Wang Z, Jia N, Liang P, Qi Z, Yang Y, et al. (2012) Changes in thalamic
connectivity in mild cognitive impairment: evidence from resting state DMRI.
Eur J Radiol 81: 277–285.
110. Nathan DE, Wang BQ, Wodlowski RD, Lin W, Yeh PH, et al. (2012)
Examining intrinsic thalamic resting state networks using graph theory analysis:
implications for fMRI detection. Conf Proc IEEE Eng Med Biol Soc 2012:
5445–5448.